(Information sent by the signatory company)
-Dante Genomics launches Avanti Software for plug-and-play genomic interpretation that takes minutes instead of hours
NEW YORK, March 20, 2023 /PRNewswire/ — Dante Genomics, a world leader in genomics and precision medicine, today launched the beta version of Avanti, the company’s proprietary B2B software for variant interpretation and redaction. reporting at scale. Avanti provides clinicians, geneticists, and researchers with a plug-and-play, web-based software user interface that generates reports in less than five minutes, in parallel, for whole genome, whole exome, target panels, and other NGS data sets. .
All genomics professionals can sign up and start generating reports in minutes at: https://avanti.dantegenomics.com
Using VCF or FASTQ files as input, Avanti returns comprehensive reports on a wide variety of clinical areas, in just minutes, running in parallel. Avanti software is platform agnostic, which means that no matter which sequencer is used, Avanti returns genomic reports and enhances the genomic offering for clinicians and researchers.
Key features include:
“We developed our Avanti software to enable Dante’s team to have speed and precision at scale, and given the success we’ve seen internally, we decided to make it available externally. With Avanti, clinics and researchers get the software they need to power their interpretation genomics,” said Andrea Riposati, CEO of Dante Genomics. “Avanti’s customer will not have to worry about expensive license fees or integration processes, or require specific knowledge of bioinformatics. We have created plug and play software so that genomics and health professionals can start working on the matter. minutes, gaining the speed and scalability we leverage at Dante Genomics for the complex interpretation of whole-genome sequencing at scale.”
Avanti software uses raw data output from any sequencer as input to create genomic reports with clinical utility and actionable medical insights.
About Dante Genomics Dante Genomics is a global genomics information company creating and commercializing a new class of transformative applications for health and longevity based on whole genome sequencing and software. The company uses its platform to deliver better patient outcomes, prevention, improved diagnostics, and personalized medicine. The company’s assets include one of the largest private consent-based genomic databases for research, proprietary software designed to unleash the power of genomic data at scale, and proprietary processes that enable an industrial approach to genomic sequencing.
Contact: Laura D’AngeloVP of Investor Relationsir@dantelabs.com 39 0862 191 0671 www.dantegenomics.com
Logo – https://mma.prnewswire.com/media/2035834…
View original content: https://www.prnewswire.com/news-releases/dante-genomics-lanza-avanti-software-para-una-interpretacion-genomica-301776226.html
